Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares sank 50% on Wednesday after the company reported interim Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback